This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0360

Metabolic modulation in psychiatry: clinical signals of the effects of incretin-based therapies on mood and cognition

METABOLIC MODULATION IN PSYCHIATRY: CLINICAL SIGNALS FROM INCRETIN BASED THERAPIES ON MOOD AND COGNITION

Early clinical signals link incretin-based therapies to mood, cognition, and inflammatory markers.

The aim is to evaluate the potential central effects of incretin-based therapies beyond glycemic control in the context of metabolic dysfunction, which is increasingly implicated in psychiatric disorders. The study was conducted as a narrative synthesis of clinical and translational studies, focusing on incretin-based therapies, psychiatric outcome measures, neuroinflammation, and central signaling pathways. The evidence points to improvements in depressive symptoms, cognition, and inflammatory markers. Proposed mechanisms involve neuroinflammatory, insulin signaling, and neuroplasticity pathways. However, in most studies, psychiatric outcome measures are secondary endpoints rather than primary targets; this is the main limitation of the evidence. As this topic bridges physical and mental health treatment, dedicated studies directly targeting psychiatric outcomes are needed.

All WCP 2026 summaries